Advertisement

Topics

XBIOTECH Company Profile

00:17 EDT 21st September 2018 | BioPortfolio

Nil

Contact

Phone: 41(0)44 789 98 46
Email: info@xbiotech.ch


News Articles [22 Associated News Articles listed on BioPortfolio]

XBiotech, Inc: XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer

Agreement Centers on XBiotech's Proprietary Manufacturing Technology to Advance Anti-NY-ESO-1 Antibody 12D7 AUSTIN, Texas, April 02, 2018 (GLOBE NEWSWIRE) -- XBiotech USA, Inc. (NASDAQ:XBIT) annou...

XBiotech Inc.: XBiotech Highlights Quarterly Developments

Company Provides Updated Overview on its Clinical, Discovery and Financial PositionAUSTIN, Texas, Aug. 10, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) provided an update on recent corpora...

XBiotech Inc.: XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart Attacks

Findings Demonstrate Ability of MABp1 (Bermekimab) to Block In Vitro Neutrophil Mediated Vascular Endothelial Activation and ThrombosisAUSTIN, Texas, Aug. 27, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc....

XBiotech, Inc: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology

XBiotech to Launch Two Phase 2 Clinical Studies to Study Subcutaneous Administration of MABp1 for Treatment of Hidradenitis Suppurativa and Atopic Dermatitis AUSTIN, Texas, April 16, 2018 (GLOBE N...

XBiotech Inc.: XBiotech gibt Zugang des weltweit führenden Kardiologen Dr. Peter Libby zu seinem wissenschaftlichen Beirat bekannt

AUSTIN, Texas, Sept. 13, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) freut sich, die Ernennung von Dr. Peter Libby zum Mitglied des wissenschaftlichen Beirats (SAB) des Unternehmens bekan...

XBiotech Inc.: XBiotech Announces Addition of World Leading Cardiologist Dr. Peter Libby to its Scientific Advisory Board

AUSTIN, Texas, Sept. 12, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) is pleased to announce the appointment of Peter Libby, MD to its Scientific Advisory Board (SAB). Dr. Libby will work ...

XBiotech Inc.: XBiotech gibt Veröffentlichung von bahnbrechenden Ergebnissen zur möglichen Rolle von Interleukin-1-alpha bei Herzinfarktrisiko bekannt

Erkenntnisse zeigen die Fähigkeit von MABp1 (Bermekimab), in vitro eine von Neutrophilen vermittelte vaskuläre endotheliale Aktivierung und Thrombose zu blockierenAUSTIN, Texas, Aug. 27, 2018 (GLOB....

XBiotech Inc.: XBiotech gibt Abschluss und positive Zwischenergebnisse für die initiale Kohorte in der Pilotstudie zu Bermekimab bei atopischer Dermatitis bekannt

Unternehmen berichtet über ein positives Sicherheitsergebnis und statistisch signifikante Verbesserungen bei Patienten mit atopischer Dermatitis, die mit einer niedrigen Dosis Bermekimab über einen....

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

More Information about "XBIOTECH" on BioPortfolio

We have published hundreds of XBIOTECH news stories on BioPortfolio along with dozens of XBIOTECH Clinical Trials and PubMed Articles about XBIOTECH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of XBIOTECH Companies in our database. You can also find out about relevant XBIOTECH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record